Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose 5% provides a source of carbohydrates for metabolism, increasing blood glucose levels and serving as a caloric supplement. Sodium chloride 0.11% supplies electrolytes to maintain osmolality and fluid balance. The combination restores intravascular volume and corrects hyponatremia or hypochloremia.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Intravenous infusion; dose determined by clinical condition and fluid/electrolyte requirements; typical maintenance: 100-200 mL/hour for adults (provides 5-10 g glucose and 0.11-0.22 g sodium chloride per hour); adjust rate based on patient status.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Not applicable as a composite entity. Dextrose: rapid clearance from plasma (half-life ~15-30 minutes) due to cellular uptake and metabolism. Sodium: no defined half-life; plasma sodium concentration is tightly regulated by renal function and ADH/aldosterone. Clinical context: infusion effects are immediate and sustained during administration; after discontinuation, plasma levels of glucose and electrolytes return to baseline within hours depending on metabolic and renal function.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Dextrose and sodium chloride are endogenous substances. Dextrose is metabolized via glycolysis and the citric acid cycle, ultimately producing CO2 (exhaled via lungs) and water. Renal excretion of intact glucose is negligible in euglycemia but occurs when blood glucose exceeds renal threshold (~10 mmol/L). Sodium and chloride are freely filtered at the glomerulus and extensively reabsorbed (≥99% for sodium) in the renal tubules; excretion is regulated by hormonal and hemodynamic factors. No biliary/fecal elimination of intact drug.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte